Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma
- 101 Downloads
The present study aimed to investigate the effectiveness of adjunctive therapy involving the Rho-associated, coiled-coil-containing protein kinase (ROCK) inhibitor ripasudil in lowering intraocular pressure (IOP) in patients with different subtypes of glaucoma, on the basis of the time of IOP measurement
In total, 58 patients who underwent adjunctive therapy with ripasudil at a single institution were included. They were classified into a primary open-angle glaucoma (POAG) group, an exfoliation glaucoma (XFG) group, and a secondary glaucoma associated with uveitis, or steroid glaucoma (SG), group. The average IOPs within 6 months before (pre-IOP) and after (post-IOP) the addition of ripasudil were compared among the 3 groups. The IOP values of the morning-visit and afternoon-visit groups were also compared to reflect the peak effectiveness of ripasudil.
The IOP reductions in the POAG (n = 38), XFG (n = 6), and SG (n = 14) groups were −1.1, +0.5, and +0.5 mmHg, respectively. Significant reductions in IOP were observed in the POAG group (P = .014). The IOP reductions in the POAG morning-visit and afternoon-visit groups were −1.9 and +0.5 mmHg, respectively. IOP was significantly reduced in the morning-visit POAG group after treatment with ripasudil (P = .002). The IOP values measured during morning visits were lower than those measured during afternoon visits (IOP reduction: −1.3 mmHg; P = .011).
The findings of the present study indicate that ripasudil is effective as an adjunctive therapy for lowering IOP in patients with POAG; these reductions are more significant when measured closer to the time of peak effectiveness.
KeywordsGlaucoma Intraocular pressure Rho-kinase inhibitor Ripasudil
Conflicts of interest
T. Komizo, Lecture fee (Kowa); T. Ono, Lecture fees (Bayer, Kowa, Santen, Senju); A. Yagi, None; K. Miyata, Grant (Novartis, Otsuka, Santen, Senju), Lecture fees (Kowa, Novartis, Otsuka, Pfizer, Santen, Senju); M. Aihara, Grant (Alcon, Pfizer), Consultant fees (Crewt Medical Systems, Glaukos, HOYA, Otsuka, Santen, Senju, WaKamoto), Lecture fees (Abbot, Alcon, Allergan, Crewt Medical Systems, HOYA, JFC Sales Plan, Kowa, Nitten, Otsuka, Pfizer, Santen, Senju, WaKamoto).
- 3.Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13.CrossRefGoogle Scholar
- 9.Xu N, Chen SH, Qu GY, Li XD, Lin W, Xue XY, et al. Fasudil inhibits proliferation and collagen synthesis and induces apoptosis of human fibroblasts derived from urethral scar via the Rho/ROCK signaling pathway. Am J Transl Res. 2017;9:1317–25.Google Scholar
- 14.Inoue K, Okayama R, Shiokawa M, Ishida K, Tomita G. Efficacy and safety of adding ripasudil to existing treatment regimens for reducing intraocular pressure. Int Ophthalmol. 2018;38:93–8.Google Scholar
- 17.Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, et al. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. Acta Ophthalmol. 2015;93:e254–60.CrossRefGoogle Scholar
- 19.Inazaki H, Kobayashi S, Anzai Y, Satoh H, Sato S, Inoue M, et al. Efficacy of the additional use of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled under maximum medical therapy. J Glaucoma. 2017;26:96–100.Google Scholar